Lipid Lowering Medication

Phase 2Small molecule

Lipid Lowering Medication is one of 82 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

HypertriglyceridemiaActive, not recruiting

Acute Myocardial InfarctionPreclinical

Active, not recruiting

HypertriglyceridemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

4 2

Adenocard

Astellas

Phase 3

2 3

Lovenox

Sanofi

Phase 3

2 4

Byetta

AstraZeneca

Phase 3

1 5

Aldactone

Pfizer

Phase 3

1 6

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

3 7

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 8

Reopro

Boehringer Ingelheim

Phase 3

1 9

Glucophage

EMD Serono

Phase 3

1 10

Neupogen

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Not yet recruiting

Women's Health

NCT06975111

Clinical

Trials by Indication[1]

Hypertriglyceridemia1 trial

Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

Completed·GGrace Therapeutics Inc.·Phase 2·NCT01516151·289 enrolled

Acute Myocardial Infarction1 trial

Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Completed·SShanghai Zhongshan Hospital··NCT06740552·1,862 enrolled

Women's Health1 trial

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Not yet recruiting·UUniversity of Colorado, Denver·Phase 2/3·NCT06975111·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lipid Lowering Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipid Lowering Medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipid Lowering Medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grace Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGrace Therapeutics Inc.

Lipid Lowering Medication

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Hypertriglyceridemia1 trial

Acute Myocardial Infarction1 trial

Women's Health1 trial

References

Drug Info

Quick Facts

Related News